GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » Degree of Operating Leverage

COLL (Collegium Pharmaceutical) Degree of Operating Leverage : -1.86 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Collegium Pharmaceutical's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -1.86. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Collegium Pharmaceutical's Degree of Operating Leverage or its related term are showing as below:

COLL's Degree of Operating Leverage is ranked better than
70.17% of 952 companies
in the Drug Manufacturers industry
Industry Median: 0.62 vs COLL: -1.86

Collegium Pharmaceutical Degree of Operating Leverage Historical Data

The historical data trend for Collegium Pharmaceutical's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Degree of Operating Leverage Chart

Collegium Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -79.96 6.43 1.40 16.37 0.74

Collegium Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.71 24.19 9.10 0.74 -1.86

Competitive Comparison of Collegium Pharmaceutical's Degree of Operating Leverage

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's Degree of Operating Leverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Degree of Operating Leverage falls into.


;
;

Collegium Pharmaceutical Degree of Operating Leverage Calculation

Collegium Pharmaceutical's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( 142.493 (Mar. 2025) / 209.163 (Mar. 2024) - 1 )/( 664.283 (Mar. 2025) / 566.923 (Mar. 2024) - 1 )
=-0.3187/0.1717
=-1.86***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Collegium Pharmaceutical  (NAS:COLL) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Collegium Pharmaceutical Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Executives
Tupper Colleen officer: EVP & Chief Financial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Scott Dreyer officer: EVP & Chief Commercial Officer 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Shirley R. Kuhlmann officer: EVP and General Counsel 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Thomas B Smith officer: EVP and Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Joseph Ciaffoni director, officer: President and CEO 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Rita J. Balice-gordon director C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Richard Malamut officer: EVP and Chief Medical Officer 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming officer: Vice President, Product Devlp 780 DEDHAM STREET, SUITE 800, CANTON MA 02021